
|Articles|July 16, 2014
Chiltern Acquires Ockham
Chiltern and Ockham announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations.
Advertisement
Chiltern and Ockham, two full-service contract research organizations (CROs), announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations.
The combined company will be called Chiltern. Ockham’s management team will join the management of the enlarged group. Chiltern’s CEO Jim Esinhart, PhD will be CEO of the Chiltern Group, with Ockham’s CEO, James V. Baker, becoming Chief Development Officer. Nick Thornton will remain as Chairman.
The merged entity combines service offerings in three areas: oncology; services and FSP/Sourcing
Read the full release
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
PLPS Launches MyClinicalSuite™ to Deliver Faster Clinical Trial Label Turnarounds Without Compromising Quality, Compliance, or Patient Safety
2
What Clinical Trials Can Learn from the Gig Economy About Payments
3
AI-Driven Clinical Trial Recruitment and Design
4
ACT Brief: RBQM Financial Value Quantified, Sponsor-Configurable AI Systems, and Basket Trials for Rare Pediatrics
5




